Related Experiment Video
Updated: Aug 21, 2026
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
Molecular mechanisms of platinum resistance: still searching for the Achilles' heel
Roman P Wernyj1, Patrice J Morin
1Laboratory of Cellular and Molecular Biology, National Institute on Aging, Baltimore, MD 21224, USA.
Abstract:
The platinum compounds cisplatin and carboplatin are commonly used in cancer chemotherapy. However, tumors frequently develop resistance to these compounds, significantly decreasing their usefulness in the clinic. In the past few years, basic research has unraveled novel and unexpected mechanisms for the development of platinum resistance. For example, it has been reported that MUC1 expression and particularly the localization of its C-terminal subunit to the mitochondria may affect cisplatin resistance. Another recent finding suggests that cisplatin damage may activate DNA-dependent protein kinase (DNA-PK) to initiate a death signal that can be transmitted to neighboring cells through gap junctions, adding to a growing belief that the interactions of cancer cells with their surroundings may be important to the outcome of chemotherapy. While most clinical efforts have focused on identifying alternative regimens for drug-resistant cancer, it might be possible to exploit our knowledge of the mechanism of platinum resistance to specifically reverse resistance and increase platinum efficacy. The strategy of drug resistance reversal therapy (DRRT) may have significant impact on our approaches to the treatment and management of drug-resistant tumors.
Insights
Novel mechanisms of platinum resistance in cancer, including MUC1 and DNA-PK pathways, are being uncovered. Understanding these pathways may lead to new strategies to reverse drug resistance and improve chemotherapy efficacy.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Medicine
Background:
- Platinum compounds like cisplatin and carboplatin are mainstays of cancer chemotherapy.
- Tumor resistance to these platinum agents significantly limits their clinical effectiveness.
- Recent research has identified novel molecular mechanisms contributing to platinum resistance.
Purpose of the Study:
- To explore newly discovered mechanisms of platinum resistance in cancer.
- To investigate the role of MUC1 expression and mitochondrial localization in cisplatin resistance.
- To examine the activation of DNA-dependent protein kinase (DNA-PK) by cisplatin and its role in intercellular signaling.
Main Methods:
- Review of recent basic research findings on platinum resistance mechanisms.
- Analysis of MUC1 expression and its subcellular localization in relation to cisplatin resistance.
- Investigation of DNA-PK activation pathways and gap junction communication in response to cisplatin treatment.
Main Results:
- MUC1 expression, particularly its C-terminal subunit in mitochondria, is implicated in cisplatin resistance.
- Cisplatin-induced DNA damage activates DNA-PK, initiating a death signal.
- This signal can be transmitted to neighboring cells via gap junctions, suggesting microenvironment interactions influence chemotherapy outcome.
Conclusions:
- Emerging mechanisms of platinum resistance involve MUC1 and DNA-PK signaling.
- Interactions between cancer cells and their microenvironment play a role in chemotherapy response.
- Targeting these resistance mechanisms through drug resistance reversal therapy (DRRT) offers a promising strategy to enhance platinum efficacy in resistant tumors.
Related Concept Videos
02:56Treatment Resistant Cancers
01:25Mechanism of Antibiotic Resistance in MRSA
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:36Mismatch Repair
00:57Antibiotic Selection